Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Azacitidine: 10 years later.

A B Glover, B R Leyland-Jones, H G Chun

    Cancer Treatment Reports
    |July 1, 1987
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The Role of Alcohol and Drug Intoxication in Fire-Related Incidents in Africa: A Systematic Review.

    Annals of burns and fire disasters·2024
    Same author

    Graded Quasiperiodic Metamaterials Perform Fractal Rainbow Trapping.

    Physical review letters·2023
    Same author

    Investigating blood alcohol concentrations in injury-related deaths before and during the COVID-19 National lockdown in Western Cape, South Africa: A cross-sectional retrospective review.

    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2023
    Same author

    Antimicrobial use in animals: a journey towards integrated surveillance.

    Revue scientifique et technique (International Office of Epizootics)·2023
    Same author

    The prevalence of children in the UK Cystic Fibrosis Registry on long term anti-Pseudomonas aeruginosa (PA) inhaled antibiotics who become culture negative for PA and a survey of practice for discontinuing treatment.

    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2023
    Same author

    Brain hyper-excitability in DPPX ataxia.

    Journal of neurology·2020
    Same journal

    Rhabdomyolysis associated with high-dose cytarabine.

    Cancer treatment reports·1987
    Same journal

    Acute laryngeal edema after single-dose irradiation and doxorubicin.

    Cancer treatment reports·1987
    Same journal

    Timing may be a critical factor in drug therapy.

    Cancer treatment reports·1987
    Same journal

    Prednimustine in advanced malignant melanoma: a phase II study.

    Cancer treatment reports·1987
    Same journal

    Phase II evaluation of diaziquone in pancreatic carcinoma: a Southwest Oncology Group Study.

    Cancer treatment reports·1987
    Same journal

    Teniposide in metastatic renal and bladder cancer: a Southwest Oncology Group Study.

    Cancer treatment reports·1987
    See all related articles

    Azacitidine is a key treatment for acute nonlymphocytic leukemia, but its optimal use in combination regimens requires further study. Future phase III trials are needed to define its precise role in leukemia treatment strategies.

    Area of Science:

    • Hematology
    • Oncology
    • Clinical Pharmacology

    Background:

    • Azacitidine has a long history in clinical trials for acute nonlymphocytic leukemia (ANLL).
    • It is recognized internationally for its therapeutic utility in ANLL.
    • The precise role of azacitidine in diverse treatment combinations remains undefined.

    Purpose of the Study:

    • To review clinical experience with azacitidine in ANLL over the past decade.
    • To identify critical information gaps regarding its application.
    • To propose feasible phase III trials for further investigation.

    Main Methods:

    • Systematic review of clinical trials and literature from the last 10 years.
    • Analysis of existing data on azacitidine efficacy and safety in ANLL regimens.

    Related Experiment Videos

  • Identification of unresolved questions and areas for future research.

    • Main Results:

    • Azacitidine is established in ANLL treatment, but its optimal combination strategy is unclear.
    • Significant data gaps exist regarding its use in induction, intensification, maintenance, and relapse settings.
    • Current evidence suggests a need for more targeted research.

    Conclusions:

    • Further research is essential to fully elucidate the role of azacitidine in ANLL treatment protocols.
    • Phase III clinical trials are recommended to define optimal combination strategies and gather critical data.
    • Clarifying azacitidine's place in therapy will improve outcomes for ANLL patients.